tradingkey.logo
搜索

Tivic Health Systems Inc

TIVC
添加自选
1.400USD
0.0000.00%
交易中 美东报价延迟15分钟
2.92M总市值
亏损市盈率 TTM

Tivic Health Systems Inc

1.400
0.0000.00%
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

0.00%

5天

0.00%

1月

+50.54%

6月

-26.70%

今年开始到现在

-3.45%

1年

-67.59%

TradingKey Tivic Health Systems Inc股票评分

单位: USD 更新时间: 2026-04-27

操作建议

Tivic Health Systems Inc当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在医疗设备与耗材行业排名146/208位。机构持股占比非常高,中期看,股价处于上升通道。近一个月,市场表现很强,基本面评分较高,但很强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Tivic Health Systems Inc评分

相关信息

行业排名
146 / 208
全市场排名
516 / 4521
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Tivic Health Systems Inc亮点

亮点风险
Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
估值低估
公司最新PE估值-0.18,处于3年历史低位
机构加仓
最新机构持股240.28K股,环比增加30.47%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值0.00

分析师目标

根据 0 位分析师
--
评级
--
目标均价
--
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Tivic Health Systems Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Tivic Health Systems Inc简介

Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
公司代码TIVC
公司Tivic Health Systems Inc
CEOErnst (Jennifer)
网址https://tivichealth.com/
KeyAI